Key Migraine Nasal Spray Market Players:
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline plc (GSK)
- Eli Lilly and Company
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Dr. Reddy's Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
- Mylan N.V. (Part of Viatris)
- Aurobindo Pharma Limited
- Amneal Pharmaceuticals, Inc.
- Lupin Limited
- Ajanta Pharma Limited
- Bausch Health Companies Inc.
- Upsher-Smith Laboratories, LLC
- Cadila Healthcare Ltd. (Zydus)
- Endo International plc
- Takeda Pharmaceutical Company Limited
- ASML Holdings N.V.
The global market for migraine nasal spray is extremely consolidated, wherein the top five players, such as Pfizer, GSK, Eli Lilly, and Teva, have captured the dominant revenue shares. The competency in this landscape emerges from R&D focused on next-generation CGRP antagonists and improved delivery systems for faster efficacy. Besides, the established organizations in this sector are facing strong competition from generic manufacturers such as Hikma and Dr. Reddy’s, owing to the affordability aspects.
Below is the list of some prominent players operating in the global market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of migraine nasal spray is estimated at USD 611.8 million.
Migraine Nasal Spray Market size was valued at USD 574.2 million in 2025 and is likely to cross USD 1.07 billion by 2035, registering more than 6.8% CAGR during the forecast period i.e., between 2026-2035.
North America predicted to garner the highest share of 45.7% by the end of 2035, impelled by increasing cases of migraine, raising awareness, and developing health care infrastructure.
The major players in the market are Upsher-Smith Laboratories, AstraZeneca plc, GlaxoSmithKline plc, Cipla Inc, Dr. Reddy’s Laboratories Ltd, Assertio Therapeutics, Inc., and Impel Neuro Pharma., Inc.
